Cytiva and Pall Announce $1.5 Billion Strategic Investment to Expand Global Life Sciences Manufacturing Capacity

-- Several major investments will expand the manufacturing capacity for life sciences products across 13 Cytiva and Pall facilities to meet customer demand.

-- The new facilities soon to open in the United States and the United Kingdom will enable a regionalized manufacturing model. Overall, these companies plan to hire 2,000 full-time employees over the next two years.

-- Prior to this investment, the company has completed five strategic acquisitions this year, complementing its ongoing capacity investments. By the end of 2022, the company's capacity investments are expected to reach $500 million.

AMERSHAM, England, July 27, 2021 /PRNewswire/ -- As companies within the Danaher (NYSE: DHR) group, Cytiva and Pall Corporation have launched a sustained strategic growth initiative aimed at serving life sciences customers worldwide.Expand Manufacturing Capacity and Services Across All Regions 。

Complementing previously announced investments, this investment is already underway and includes the construction of new facilities and the expansion of existing plants. Prior to this, the company has completed five acquisitions year-to-date.

Danaher executive Emmanuel Ligner stated: “Our customers have told us they need manufacturing agility, a robust global supply chain, and more regional options. This investment further advances our expansion plans, enabling us to rapidly meet the current and future needs of our customers and, ultimately, their patients.”

Cytiva and Pall Corporation's capacity expansion will increase the production of critical products used in biopharmaceutical manufacturing.

Upcoming Company Investment:

This investment also addresses the research conducted by Longitude, a subsidiary of the Financial Times.《Global Biopharma Resilience Index》Some of the key challenges highlighted in the survey report. The report was published by Cytiva in March 2021. These challenges include talent recruitment and training, R&D collaboration, supply chain resilience, manufacturing models, and government policies and regulations.

AboutPall
Pall Corporationis aA leading company in filtration, separation, and purification, providing solutions that meet the critical fluid management needs of customers across life sciences and a wide range of industries.WorkforDanaher（New York Stock Exchange Ticker Symbol:DHR）Science and Techpart of the family of technology innovators,Pallwith customersPartner with customers to advance healthy, safe, and environmentally responsible technologies.Corporate EngineeringThe product enables process and product innovation while minimizing emissions and waste.Pall CorporationServing customers worldwide. For more information, please visitwww.pall.com。

AboutCytiva
Cytivais a global life sciencesa leader in the field, at40countries and regionsWith over8000NameEmployees, dedicated to advancing and accelerating the development of various therapies. CytivaYesDanaher（NYSE Ticker Symbol:DHR) Science and TechnologyAs part of a family of technology innovators, we are a trusted partner to customers of all sizes and across diverse fields.CytivaBrings speed, efficiency, and capability to research and manufacturing workflows, enabling the development, manufacturing, and delivery of transformative medicines to patients. For more information, visitwww.cytiva.com。